Hervé Bonnefoi is an expert in Oncology at Institut Bergonié (France). As of July 2026, ScienceLeadR ranks Hervé Bonnefoi in the top 1% of experts worldwide for Breast Neoplasms and Breast Diseases. Hervé Bonnefoi has authored 289 publications, the most recent in 2026, and is an investigator in 27 clinical trials. SLR score: 1,063 (community average: 125). How the SLR is computed.

LeadR Profile

Hervé Bonnefoi Institut Bergonié France
1 063 ScienceLeadR Reputation 1063
Network Map

Oncology

Subspecialties: Dermatology - Pharmacy - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2001 - 2026

Source: PubMed

Institut Bergonié

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 289

Citations

Citations: 31 440 1st author: 35 Last author: 25 Unique author: 8


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Tracking structural variants in early breast cancer using a high-sensitivity ctDNA assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trial.
PMID 42242004 — breast neoplasms, neoplasms, breast, therapeutics, plasma
ESMO Open20260
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.
PMID 42229584 — breast neoplasms, neoplasms, drug therapy, hormones, breast, therapeutics, tamoxifen, chemotherapy
Ann Oncol Top journal20260
Clinical and Molecular Evaluation of HER2-Low and Ultralow Breast Cancer in the PENELOPE-B Clinical Trial Cohort.
PMID 42025846 — breast neoplasms, neoplasms, pathology, biomarkers, breast, therapeutics
Mod Pathol20260
Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index.
PMID 41182766 — breast neoplasms, ovary, neoplasms, biomarkers, hormones, clinical medicine, breast, therapeutics, tamoxifen
JAMA Netw Open20251
Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies.
PMID 40893049 — breast neoplasms, neoplasms, breast, precision medicine, therapeutics, genes, brca1, mutation
JCO Precis Oncol20250

Clinical Studies 27

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1 Study Chair: 5

By phase:

Phase 3 12
Phase 2 10
N/A 2
Phase 1/Phase 2 2

By status:

Completed 22
Active not recruiting 2
Recruiting 1
Terminated 1

By type:

Interventional 25
Observational 1

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 1
multicentric5to9 0
multicentricup10 22

Main Topics

Cohort/Consortium Investigators 2

LeadR Networks

Main global connection map